Product Details
| Product Name:
GNF4877 |
CAS No.:
2041073-22-5 |
| Purity:
99.40% |
Supply Ability:
10g |
| Release date:
2026/05/26 |
Product Introduction
Bioactivity
| Name | GNF4877 |
| Description | GNF4877 is a small molecule inhibitor, a potent dual-specificity kinase inhibitor targeting DYRK1A (IC50=6 nM) and GSK3β (IC50=16 nM). This compound promotes β-cell proliferation by blocking NFATc nuclear export (EC50=0.66 μM for mouse R7T1 cells) and is primarily used for research on β-cell regeneration related to diabetes. |
| In vitro | Methods: Mouse β-cells (such as R7T1 cells) were treated with low concentrations of GNF4877 (0.1, 0.3 μM) in combination with high glucose, glucokinase activators (GKAs), glibenclamide, or Bay K8644 to detect cell proliferation, Ca2? signaling, and NFATc nuclear translocation.
Results: Low concentrations of GNF4877 promoted β-cell proliferation under high glucose or GKA stimulation; high glucose and GKAs enhanced Ca2? signaling, activated calcineurin, and promoted NFATc nuclear translocation; glibenclamide or Bay K8644 increased intracellular Ca2? and showed additive effects with GNF4877. [1] |
| In vivo | Methods: A mouse β-cell model was used, and low concentrations of GNF4877 (0.1, 0.3 μM) combined with high glucose or glucokinase activators (GKAs) were applied to detect cell proliferation; the effects of high glucose and GKAs on Ca2? signaling, calcineurin activation, and NFATc nuclear translocation were also evaluated; additionally, glibenclamide or Bay K8644 combined with GNF4877 were used to detect synergistic effects.
Results: Low concentrations of GNF4877 promoted β-cell proliferation under high glucose or GKA stimulation; high glucose and GKAs enhanced Ca2? signaling, activated calcineurin, and promoted NFATc nuclear translocation; glibenclamide or Bay K8644 increased intracellular Ca2? and showed additive effects with GNF4877. [1] |
| Storage | Keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 6.94 mg/mL (14.03 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | GSK-3β | GSK3β | GSK-3 | GSK3 | GNF-4877 | GNF4877 | GNF 4877 | Glycogen synthase kinase-3 | Glycogen synthase kinase 3 | DYRK1A | DYRK | Dual specificity tyrosine regulated kinase | Dual specificity tyrosine phosphorylation regulated kinase |
| Inhibitors Related | Cromolyn sodium | 4-Methyl-6-Methoxycoumarin | Indazole | GSK 3 Inhibitor IX | AT7519 | 5-Bromoindole | 4-Chloro-2'-bromoacetophenone | Ethyl linoleate | Ginsenoside Rg2 | GSK-3 Inhibitor 5 | (E/Z)-10-Hydroxy-2-decenoic acid | ROCK-IN-5 |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Neuroprotective Compound Library | Inhibitor Library | Anti-Fibrosis Compound Library | NO PAINS Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$56.00
|
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-26 |
United States